A pharmaceutical composition for the treatment of otic disorders, such as Menieres disease or sudden sensineural hearing loss, is disclosed, wherein the sustained release of the corticosteroids dexamethasone, methylprednisolone or prednisolone is provided into the cochlea for at least 14 days. The composition comprises a corticosteroid and between 16-21% by weight polyoxyethylene-polyoxypropylene triblock copolymer of the formula E106 P70 E106, and water buffered to a perlymph-suitable pH, and has a perilymph suitable osmolarity of between 250-320mMm and contains less than 50 colony forming unit microbial agents per gram of formulation. The formulation is preferably in the form of an auris-acceptable thermoreversible gel, and the sustained release matrix preferably comprises Pluronic F-127 RTM (poloxamer 407).
